Medidata turns loss to profit in Q2

By Nick Taylor

- Last updated on GMT

Medidata has followed its successful IPO by posting an operating profit in Q2, having made a loss last year, and giving a positive outlook for the rest of the year.

In June Medidata became the first company this year that has never made an annual profit to file an initial public offering (IPO). The IPO was successful, raising $82m (€57.4m), and Medidata is now on course to make a small net profit in fiscal 2009.

Bruce Dalziel, chief financial officer at Medidata, believes this turnaround is a consequence of establishing the presence and infrastructure during its decade as a private company.

Over this period Medidata formed business relationships with many companies, including Roche and Almac, and this attracted investors to its IPO.

Its relationships have also helped it create a backlog that should generate revenues of $62.9m by the end of the year. Medidata predicted that its 2009 net income would be $0-2m and financial markets responded positively to this news, sending the company’s shares up by 11 per cent.

The year so far

The first two quarters of 2009 have given Medidata the platform to achieve its profitability goal. In the second quarter the company had an operating income of $773,000, compared with a $5.5m loss in the same period of 2008.

A 32 per cent rise in total revenues, taking it up to $34m, was partially responsible but other factors also applied. Despite the increase in sales Medidata managed to keep the cost of revenues down, with this figure falling by four per cent.

These two factors helped Medidata increase its gross profit by 69 per cent to $21.3m. In the first six months of fiscal 2009 Medidata made an operating income of $3.1m, compared to a loss of $13.3m in the corresponding period of last year.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars